This is the first report to describe the potential for classification of cancer using anti-phosphoprotein monoclonal antibodies (PPmAbs) and multiple discriminant analysis. Over 150 hybridoma clones producing monoclonal antibodies were generated against a human phosphoprotein mixture derived from a human leukemia cell line. The expression profiles of 22 cell lines from 9 different types of cancer using PPmAbs were examined. The relationship between cancer cells and the expression of human phosphoprotein in the cells was analyzed by multiple discriminant analysis and was used to construct a diagnostic system for cancers. Multiple discriminant analysis was able to successfully classify the cell lines into the correct cancer group by using the diagnostic system for cancers. These results show that multiple discriminant analysis based on phosphoprotein expression in cells or tissues may be a potentially valuable method for assisting in the classification of several cancers.
Post-translational modification of proteins is one of the major determinants of organism complexity (1) . One of the most studied post-translational modifications is phosphorylation, because cellular phosphoproteins are involved in numerous signaling pathways. The most significant role of phosphorylation is to act as a switch to turn "on" and "off" protein activity or a cell-signaling pathway in an acute and reversible manner (8) . Therefore, disruption of phosphorylation and/or intracellular signaling by mutation of phosphoproteins is central to many different chronic diseases, including cancer. Recently, many different tools for comprehensively analyzing phosphoproteins have been developed using proteomics-based technology, which were coined "phosphoproteomics." Phosphoproteomics include 2-dimensional gel electrophoresis, direct staining of phosphoproteins using several fluorescent phosphosensor dyes (5), and surface-enhanced laser desorption-ionization time-offlight mass spectrometry (9) . Although numerous cancer proteome studies have been performed in many laboratories across the world, these studies have been focused on the expression of relatively abundant and specifically cancer-related proteins. Hirohashi et al. reported a unique immunization procedure using a gastric cancer xenograft as an immunogen (4) . The authors succeeded in developing monoclonal antibodies (mAbs) reactive to hitherto unknown tumor-associated antigens in whole cancer tissues. We have previously produced anti-human phosphoprotein mAbs (PPmAbs) using a phosphoprotein mixture that was not purified and not identified, and termed this immunization procedure "random immunization." The Freund's complete adjuvant. Mice were subsequently injected i.p. on a further 4 occasions at 2-weekly intervals with 100 μg immunogen emulsified with Freund's incomplete adjuvant. Immune splenocytes were fused with SP2/0-Ag14 murine myeloma cells using polyethylene glycol 2,000, and hybridoma cells were generated in hypoxanthine/aminopterin/ thymidine culture medium (6) . Hybridoma supernatants were screened for anti-phosphoprotein activity by indirect immunofluorescence assay (IFA) using methanol-fixed Molt-4 cells as antigen (7). Hybridomas producing anti-phosphoprotein antibodies were sub-cloned twice by the limiting dilution method; 154 clones secreting anti-PPmAbs were identified. All PPmAbs were tested by IFA for reactivity with methanol-fixed Molt-4 cells. Staining patterns by IFA were grouped into 6 types, namely, full peripheral (Fig. 1A ), partial peripheral (Fig. 1B) , shaggy ( Fig. 1C) , shaggy + peripheral (Fig. 1D ), peripheral dot ( Fig. 1E) , and homogenous dot (Fig. 1F) . No reactivity was observed with fluorescein isothiocyanateconjugated anti-mouse immunoglobulin as secondary antibody. The 154 PPmAbs displayed several reactive patprocedure has the following advantages: (i) it does not require a high degree of purification of the immunogen; (ii) it is able to establish hybridomas producing mAbs against several phosphoprotein specificities at the same time; and (iii) it may result in the incidental discovery of hitherto unknown tumor markers. Multiple discriminant analysis is a mathematical method that may be used for the profiling of phosphoprotein expression in cancer cells and may improve the classification power, thereby increasing the final discrimination rate (2) . By means of a suitable computer program, working with PPmAbs, we investigated the possibility of enhancing the differentiation between cancers and assessed the prediction of cancer diagnosis based on phosphoprotein expression profiling analyzed by multiple discriminant analysis. A phosphoprotein enrichment kit for isolating phosphorylated proteins as an immunogen from Molt-4 human leukemia cell lysate was purchased from Clontech (CA, USA; catalog no. 635624) (11) . BALB/C mice were intraperitoneally (i.p.) injected with 100 μg of the immunogen emulsified with terns with different cancer cell lines by IFA, dependent on staining type and strength. As the raw data of reactivity cannot be standardized between PPmAbs, the staining strength was represented as "0" (negative reaction) or "1" (positive reaction) for multiple discriminant analysis, regardless of staining pattern. PPmAbs showing the same reaction pattern were discarded, resulting in the final selection of 54 PPmAbs. Several combinations of PPmAbs were examined by multiple discriminant analysis for the classification of the cancer cell lines; combinations consisting of less than the 21 PPmAbs listed in Table 1 could not be used to successfully classify the cancer cell lines. The results of multiple discriminant analysis using IBM SPSS ver. 19 software are shown in Table 2 . When a scattergraph was drawn for Function 1 against Function 2, each cancer cell line was classified into the correct cancer group (Fig. 2) . Function 1 and Function 2 represent discriminant functions and discriminant scores, respectively, which are used to maximize the distance between the different cancer groups on a scattergraph. We next examined whether other new cancer cell lines (Li-7: liver cancer, Lu130: lung cancer) 
